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Background: The regular intake of probiotics is alleged to help prevent or shorten the duration of common colds
and gastrointestinal diseases. Previous clinical trials have shown protective effects in young children, while effects in
adults have not yet been sufficiently investigated.
Methods: This study examines the effect of the regular intake of the probiotic Lactobacillus reuteri (DSM 17938) on
the number of days of sick leave caused by respiratory and gastrointestinal diseases among male steelworkers. For
this RCT, 242 male employees of ArcelorMittal Bremen were randomized. One hundred and twenty-one participants
were assigned to take one chewable tablet containing at least 5 × 108 colony-forming units of L. reuteri per day over
a period of 90 days. The 121 control participants were assigned to take a placebo. All participants were asked to
keep a diary reporting days of sick leave and respiratory and gastrointestinal symptoms. Data of 159 participants
were available for intention-to-treat analysis.
Results: Participants in the intervention group reported sick due to respiratory and gastrointestinal symptoms at an
average of 2.24 of the 90 days under observation. In the control group, the average number of sick days was 2.02
(p = 0.53). Prevention of diarrhea was the only protective effect detected for the probiotic. Participants in the
intervention group reported this symptom at an average of 0.60, participants in the control group at 1.33 days
(p = 0.01).
Conclusions: Our study could not show an effect of the intake of L. reuteri on the number of days of sick leave or
on any of the symptoms of respiratory and gastrointestinal diseases with the exception of diarrhea.
The trial was registered in the German Clinical Trials Register on November 7, 2012 (www.germanctr.de; No.:
DRKS00004430).
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Figure 1 Flow chart.
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Work in the steel industry is related to stress factors
which can negatively affect an employee’s health. Alter-
nating shifts, heavy physical work, and stressful environ-
mental influences such as heat, noise, and dust lead to
high rates of sick leave in this industry [1].
ArcelorMittal Bremen, part of the international steel
group ArcelorMittal, observed a high and in recent years
increasing rate of sick leave with a considerable portion
caused by respiratory and gastrointestinal diseases (mainly
common colds and diarrheal diseases).
Several studies have shown that the regular intake of a
probiotic may prevent the occurrence or reduce the dur-
ation of respiratory and gastrointestinal diseases [2-6]. The
Food and Agriculture Organization of the United Nations
(FAO) and the World Health Organization (WHO) define
probiotics as “Live microorganisms which when adminis-
tered in adequate amounts confer a health benefit on the
host” [7].
As of December 2013, we could only find one clinical
trial investigating the effects of the intake of Lactobacillus
reuteri on the rate of sick leave due to common colds and
gastrointestinal diseases in adults (see Appendix). The
randomized placebo-controlled trial was carried out at the
multinational packaging company Tetra Pak in Sweden
and showed a significant reduction of days of sick leave in
the group randomized to the use of L. reuteri [8].
Numerous trials have demonstrated the safety of the
probiotic L. reuteri. No side effects or adverse events were
observed up to a daily dose of 1011 colony-forming units
(CFUs) [9-14].
However, studies have not yet demonstrated the safety
of the intake of some probiotic strains for people with
preexisting conditions like diabetes, cancer, abscesses,
pancreatitis, HIV, and organ transplants [14-18].
The present study examines whether the regular intake
of L. reuteri is able to positively affect the rates of sick
leave of male employees in the steel industry.
Methods
This double-blind randomized placebo-controlled parallel
group design trial took place at ArcelorMittal Bremen. It
was carried out from June 2012 to June 2013 (with the
intervention period running from December 2012 to May
2013) and was initiated by ArcelorMittal due to high rates
of sick leave in the steel production.
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all proce-
dures involving human subjects were approved by the eth-
ics committee of the Bremen State Medical Council.
Written informed consent was obtained from all subjects.
Our target population was 671 male employees work-
ing at the blast furnace and the hot strip mill at the
ArcelorMittal steel company in Bremen, comprising shiftworkers performing heavy physical work as well as em-
ployees without alternating shifts and mostly engaged in
sedentary work. These employees were informed about
the planned research project via posters, flyers, and in-
formational lectures.
Because of the low proportion of female employees in the
participating working areas (about 1.8%), the study sample
exclusively consists of men aged between 18 and 65 years.
Persons with a history of diabetes, cancer, abscesses, pan-
creatitis, HIV, and organ transplants were excluded from
the study due to the not yet verified harmlessness of some
probiotic strains for patients with these preexisting condi-
tions [14-18]. As shown in Figure 1, seven individuals had
to be excluded.
Study participants were randomly assigned to the inter-
vention or control group using a computer-generated list
of random numbers. Participants in the intervention group
were assigned to take one chewable tablet containing at
least 5 × 108 colony-forming units of L. reuteri per day over
a period of 90 days. Other ingredients of the tablets were
isomalt, xylitol, palm oil, lemon-lime flavoring, and citric
acid. Over the same period of time, participants in the con-
trol group were required to take one placebo tablet per
day, consisting of the same ingredients as the verum tablets
except for L. reuteri. Verum and placebo were provided
free of charge in sealed vials labeled A and B by BioGaia,
Sweden, without any conditions. The vials contained 30
tablets and were refilled if lost. No pill counts were
made as trade union representatives of ArcelorMittal
had objected to any control measures.
With the recruitment running from December 2012 to
February 2013, volunteers who had signed informed con-
sent were requested to fill out a questionnaire recording
year and country of birth, body height, and weight as well
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intervention period, running from December 2012 until
May 2013, participants were asked to report in diary for-
mat respiratory and gastrointestinal symptoms such as
cough, common cold, hoarseness, sore throat, earache,
headache, fever, stomachache, diarrhea, and vomiting and
their days of absence from work due to any of these symp-
toms by checking boxes in their prepared diaries once a
day. The reported number of days absent from work was
analyzed as the primary outcome, the symptoms as sec-
ondary outcomes.
Power calculations with an α-error = 0.05, β = 0.1, and
an anticipated difference in days absent from work be-
tween the two groups of 0.9 over 90 days had set the re-
quired number of individuals at 96 per group. Nper Group =
2 × [(1.96 + 1.28) × 1.92/0.9]2 = 96.
With an expected loss to follow-up of 20%, a mini-
mum of 116 participants per group was required.
Data were analyzed using “SPSS 15.0” (www.ibm.
com/software/de/analytics/spss). Data of participants
who dropped out of the study before the end of the inter-
vention period without revoking their consent were extrap-
olated to 90 days for the intention-to-treat analysis (n = 17).
Chi-square test, t-test, and Fisher’s exact test were used for
the comparison of the sample characteristics in the inter-
vention and control group. The primary and secondary out-
comes were analyzed using the Wilcoxon-Mann–Whitney
U-test as the data did not follow a normal distribution.
All statistical analyses are based on blinded data. The
information whether the vials labeled A or B contained
the active probiotic was only available to BioGaia and to
an independent employee at Bremen University, who
made that decision. The allocation seal was not broken
until all analyses were completed.
All parts of the study (design, development of mate-
rials, enrollment of participants, data collection, analysis)
were carried out by the authors of this paper.Results
Two hundred and forty-nine of the 671 eligible employees
agreed to participate in the study (37.1%, Figure 1). Seven
volunteers were excluded due to preexisting conditions so
that 242 employees were randomized. Eighty-three partici-
pants did not return their study diaries and could there-
fore not be included in the statistical analysis. In total, the
analysis is based on 159 of 242 randomized participants
corresponding to a drop-out rate of 34.3%.
The two groups were similar with regard to age, body
weight, country of birth, working conditions, and most
lifestyle habits (Table 1). The only discrepant finding
was a higher consumption of probiotic foods like pro-
biotic yogurts and yogurt drinks in the control group on
a daily basis or several times a week (p = 0.04).Effect of the probiotic on days of sick leave
Participants in the intervention group reported 176.9 days
of sick leave due to respiratory and gastrointestinal symp-
toms per 7,110 days of observation (2.49%), while partici-
pants in the control group missed 161.5 days of work for
this reason per 7,200 days of observation (2.24%) (Table 2).
The average number of sick days per participant during
the intervention period was 2.24 in the intervention and
2.02 in the control group (p = 0.53).
The longest cumulative absence from work for a single
participant was 30 days in the intervention group and
24 days in the control group. Approximately 65% of the
study subjects in the intervention group and 70% in the
control group reported zero days of sick leave due to re-
spiratory and gastrointestinal symptoms during the inter-
vention period.
The 28 participants in the intervention group with at
least one day of sick leave due to respiratory and gastro-
intestinal symptoms reported sick on an average of
6.3 days. The 24 participants in the control group with
at least one day of sick leave caused by the same symp-
toms reported sick on an average of 6.7 days (p = 0.71).
Effect of the probiotic on symptoms of respiratory and
gastrointestinal diseases
One or more symptoms on at least one of the 90 inter-
vention days were reported by 84.8% of the participants
in the intervention group and by 87.5% of the partici-
pants in the control group (p = 0.62; Table 3). Analysis
by distinct symptoms was balanced in the study groups.
The only significant difference was a protective effect
observed for L. reuteri for diarrhea. Diarrhea occurred in
20.3% of the intervention group and in 37.5% of the con-
trol subjects (p = 0.02).
No differences were detected concerning the average
number of days with symptoms during the intervention
period (Table 4). Again, the only observed benefit was a
lower incidence of diarrhea. On average, diarrhea was
reported on 0.60 days for participants in the intervention
group (1.33 days in the control group; p = 0.01).
Almost all of the recorded symptoms occurred more
frequently in individuals assigned to placebo. This trend
can also be seen when adding up all the individual symp-
toms each participant reported over the 90 intervention
days. On average, participants in the control group re-
ported 42.5 out of a possible 900 individual symptoms
during the 90 days of the intervention. Participants in the
intervention group reported on average 32.67 symptoms
(p = 0.25).
No harms or unintended effects were reported.
Discussion
This randomized controlled trial did not detect an effect
of the probiotic L. reuteri on the number of days of sick
Table 1 Characteristics of the study population
Intervention group (n = 121) Control group (n = 121) p-valuea
Age:
Mean (SD) 41.7 years (9.9) 41.7 years (9.6) 1.0
Minimum-maximum 19–61 19–58
< 30 19 (15.7%) 17 (14.0%) 0.62
30 to <40 30 (24.8%) 24 (19.8%)
40 to <50 42 (34.7%) 51 (42.1%)
50 to <60 29 (24.0%) 29 (24.0%)
60+ 1 (0.8%) 0 (0.0%)
BMI:
Mean (SD) 27.8 (3.9) 27.5 (3.8) 95% CI, −0.7 to 1.2, p = 0.57
Min-max 18.4–40.2 17.9–36.8
Underweight 1 (0.8%) 1 (0.8%) 0.96
Normal 29 (24.0%) 30 (24.8%)
Overweight 56 (46.3%) 57 (47.1%)
Obesity 35 (28.9%) 33 (27.3%)
Country of birth:
Germany 103 (85.1%) 98 (81.0%) 0.17
Turkey 11 (9.1%) 8 (6.6%)
Others 7 (5.8%) 15 (12.4%)
Work:
Shift work 60 (49.6%) 66 (54.5%) 0.44
Part time 2 (1.7%) 1 (0.8%) 1,0b
Mostly standing 69 (57.0%) 72 (59.5%) 0.75
Mostly sedentary 47 (38.8%) 45 (37.2%)
Reported working exposures:
Noise 69 (57.0%) 76 (62.8%) 0.36
Temperature fluctuations 66 (54.5%) 76 (62.8%) 0.19
Heat 42 (34.7%) 51 (42.1%) 0.28
Cold 49 (40.5%) 52 (43.0%) 0.61
Dust 65 (53.7%) 76 (62.8%) 0.15
Carbon dioxide 24 (19.8%) 23 (19.0%) 0.82
Smoke 22 (18.2%) 26 (21.5%) 0.63
Heavy lifting/carrying 32 (26.4%) 31 (25.6%) 0.85
Mental stress 74 (61.2%) 69 (57.0%) 0.51
Frequent lifestyle habits:
Smoking 41 (33.9%) 39 (32.2%) 0.79
Alcohol consumption 8 (6.6%) 7 (5.8%) 0.79
Physical activities 43 (35.5%) 46 (38.0%) 0.69
Consumption of fruits and vegetables 87 (71.9%) 99 (81.8%) 0.07
Consumption of probiotic foods 4 (3.3%) 12 (9.9%) 0.04
Flu vaccination 16 (13.2%) 12 (9.9%) 0.44
ap-values calculated using chi-square test or t-test.
bp-value calculated using Fisher’s exact test.
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Table 2 Days of sick leave due to respiratory and






Total number of days under
observation
7,110 7,200
Total number of days of sick
leave due to respiratory and
gastrointestinal diseases
176.9 161.5
Number of days of sick leave
as a percentage of the days
under observation
2.49% 2.24%
Number of days of sick leave
per participant
Mean 2.24 2.02
Standard deviation 4.74 4.28
Minimum 0 0
Maximum 30 24
Number of participants with
at least one day of sick leave
during the intervention period
28 (35.4%) 24 (30.0%)
Number of days of sick leave
for participants with at least
one day of sick leave
Median 5.0 5.0
Mean 6.32 6.73
Standard deviation 6.19 5.45
Minimum 1 1
Maximum 30 24
Table 3 Participants with symptoms on at least one day






Cough 50 (63.3%) 51 (63.8%) 0.95
Common cold 61 (77.2%) 57 (71.3%) 0.39
Hoarseness 35 (44.3%) 32 (40.0%) 0.58
Sore throat 38 (48.1%) 48 (60.0%) 0.13
Earache 12 (15.2%) 11 (13.8%) 0.80
Headache 47 (59.5%) 53 (66.3%) 0.38
Fever 18 (22.8%) 21 (26.3%) 0.61
Stomachache 19 (24.1%) 22 (27.5%) 0.62
Diarrhea 16 (20.3%) 30 (37.5%) 0.02
Vomiting 8 (10.1%) 2 (2.5%) 0.06b
Any symptom 67 (84.8%) 70 (87.5%) 0.62
ap-values calculated using chi-square test or t-test.
bp-value calculated using Fisher’s exact test.







Cough 7.52 10.79 0.67
Common cold 10.38 13.81 0.51
Hoarseness 3.34 3.50 0.91
Sore throat 3.92 4.37 0.26
Earache 1.19 0.95 0.75
Headache 3.53 5.42 0.16
Fever 1.02 0.99 0.73
Stomachache 0.96 1.30 0.58
Diarrhea 0.60 1.33 0.01
Vomiting 0.21 0.04 b
Any symptom 32.67 42.50 0.25
ap-values calculated using chi-square test or t-test.
bStatistical analysis not possible due to low case frequency.
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among male employees in the steel industry.
Our results stand in contrast to the findings of the
slightly larger trial by Tubelius et al. 2005 [8], which
took place at the Tetra Pak company in Sweden and
which also investigated the effects of the regular intake
of L. reuteri on sick leave caused by symptoms related to
the respiratory and gastrointestinal tracts. In that study
altogether, 262 volunteers were randomized to take ei-
ther the probiotic (108 CFU per day) or a placebo over a
period of 80 days. With a loss to follow-up of 31%, 181
participants were included showing a strong protective
effect for the intake of L. reuteri: Of the study subjects,
26.4% in the control group and 10.6% in the intervention
group reported sick due to respiratory or gastrointestinal
infections during the intervention period (p < 0.01). On
average, participants in the control group reported sick
on 0.9% of the study days, participants in the interven-
tion group on 0.4% of the study days (p < 0.01).
The discrepant findings between the Swedish trial and
ours may be due to the different workplace settings. Ex-
cept for average age, sex, and whether or not the partici-
pants were shift workers, however, the publication of theTetra Pak trial provides no further information about the
participants’ working conditions and lifestyle habits. No
further information about the statistical analysis were pro-
vided. A comprehensive comparison of the two clinical tri-
als was not possible due to this lack of information.
A per-protocol analysis in our study, which only included
participants who reported having taken the chewable tab-
lets on at least 90% of the intervention days (n = 144), did
not show a significant effect of the probiotic on the number
of sick days due to respiratory or gastrointestinal symptoms
either. The average number of sick days per participant
during the intervention period was 2.05 in the intervention
and 2.01 in the control group (p = 0.81).
Our study was unable to detect an effect of L. reuteri on
almost any of the symptoms covered by the questionnaire.
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cant preventive effects of regular intake. These findings
comply with results of various other clinical trials, mostly
examining infants and children, which already demon-
strated this protective effect on the occurrence of diarrhea
[3,19-26]. This could also be a chance finding due to mul-
tiple testing.
The described trend that almost all of the symptoms
occurred at a lower rate in the intervention than in the
control group suggests that the probiotic may have a
protective effect even though the results were not statis-
tically significant. The fact that statistical significance
was not achieved may have been caused by the relatively
low rate of returned study diaries.
The predefined power of the trial of 90% could not be
achieved due to the high rate of missing data. An ex-post
power calculation, based on the anticipated assumptions
but considering the actual number of participants, re-
vealed an actual power of 83.8%.
Data of participants who did not complete the whole
90 days of the intervention were included in the intention-
to-treat analysis. The daily statement of the participants in
their study diaries whether they took the tablet or not was
the only way to control intake and the only available infor-
mation on which the per-protocol analysis could be based.
Like all other collected data in this trial, the information
about the intake of the probiotic is a statement by the
study subjects that could not be verified.
No pill counts were conducted due to restrictions by
ArcelorMittal’s works committee. Pill counts would also
have required greater commitment on the part of the
volunteers and might thereby have discouraged em-
ployees from participating. In principle, it is possible to
test compliance by measuring the concentration of L.
reuteri in fecal specimens. That approach would have
decreased the number of volunteers substantially and
would not have been feasible given the available financial
and human resources. Furthermore, it was not possible
to validate information on frequency of sick leave by
accessing the company’s internal data due to data pro-
tection regulations.
The randomization was largely successful. As shown
in Table 1, participants in the intervention and in the
control group have similar characteristics. The only sta-
tistically significant difference observed between the two
groups was the frequency of the consumption of pro-
biotic foods. It can be assumed, however, that this differ-
ence did not result in a relevant decrease in the
observed effect of the probiotic because the share of
study subjects who reported having consumed probiotic
foods regularly was less than 10% even in the control
group. Furthermore, probiotic foods most often contain
such small amounts of active microorganisms that their
health effects are questionable.Selection bias caused by healthy volunteers may have
been present in our study but should have affected
both intervention groups due to random allocation.
Moreover, our results can only be generalized to com-
panies in the steel industry and not to the general
population due to the specific characteristics of the ex-
amined sample.Conclusions
The probiotic L. reuteri did not affect the number of
days of sick leave caused by respiratory and gastrointes-
tinal diseases in our study. The results suggest that there
might be a protective effect on the symptoms of the
mentioned diseases even though only the effect on the
occurrence of diarrhea reached statistical significance.
As our literature research via PubMed showed, the ef-
fects of probiotics on the development of respiratory
and gastrointestinal diseases in adults have not yet been
adequately investigated. Further scientific research is ne-
cessary to verify the results of the current and previous
clinical trials. As the safety of L. reuteri has already been
shown for much higher dosages, it might be appropriate
for future studies to investigate the effects of a higher
dose. In any case, these studies should include measure-
ments of compliance in addition to information col-
lected by diaries.Appendix
Our search in the MEDLINE database restricted to
“Clinical Trials” AND “Lactobacillus reuteri” yielded 89
hits. Of these 89 publications, published between April
1997 and August 2013, 78 investigated the effects of L.
reuteri in humans (49 in adults, 29 in infants, children,
and adolescents). These 78 publications mainly focused
on oral health (33 studies) and gastrointestinal diseases
like diarrhea (24 studies). Other studies investigated the
safety of L. reuteri (six studies) and the effects on vaginal
infections (nine studies), Helicobacter pylori infections
(five studies), allergies (five studies), respiratory diseases
(three studies), cholesterol level (two studies), rheuma-
tism (one study), and obesity (one study).
Several clinical trials observed a correlation between
lower incidences and shorter durations of gastrointes-
tinal diseases and the regular intake of L. reuteri
[11,19-21,25,26].
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